Good play on a speculative migraine pain management device.
Around 600 M shares outstanding with low float and virtually no debt.
A small investment in $ADHC could yield exponential returns in a few short years.
Market cap could exceed to over $1B+ with successful FDA and clinical studies then successful marketplace execution.
Over $1 PPS is not unreasonable with this massive pain management market.
Good luck to longs.
Around 600 M shares outstanding with low float and virtually no debt.
A small investment in $ADHC could yield exponential returns in a few short years.
Market cap could exceed to over $1B+ with successful FDA and clinical studies then successful marketplace execution.
Over $1 PPS is not unreasonable with this massive pain management market.
Good luck to longs.